Navigation Links
Financial in Biological Technology

SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results

BOTHELL, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD ) today reported financial results for the three and six months ended June 30, 2009. Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions with a number o...

Novavax Reports Second Quarter 2009 Financial Results

ROCKVILLE, Md., Aug. 7 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) today reported a net loss of $8.5 million, or $0.10 per share, for the second quarter of 2009 compared to a net loss of $9.4 million, or $0.15 per share, for the second quarter of 2008. For the six month...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

CORAL GABLES, Fla., Aug. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported financial results for the second quarter and six months ended June 30, 2009. Second Quarter 2009 Results For the quarter ended June 30, 2009, th...

American Oriental Bioengineering Reports Second Quarter 2009 Financial Results

NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- --2Q09 Revenue Increased 20.7% YoY to $71.2 Million-- --2Q09 Net Income Attributable to Controlling Interest was $13.2 million or $0.17 per Diluted Share-- -- Company Generates Approximately $...

AutoImmune Inc. Reports 2009 Second Quarter Financial Results

PASADENA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, for th...

GenVec Reports Second Quarter 2009 Financial Results

GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today announced its financial results for the second quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) GenVec reported a net loss of $4.8 milli...

Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release r...

Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. ...

Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009

NEWTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today that the Company will release second quarter 2009 financial results on Tuesday, August 11, 2009, before the opening of the U.S. financial markets. Mi...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per shar...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM ), today reported its financial results for the quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) Second Quarter Results Total revenue fo...

OncoGenex Reports Second Quarter 2009 Financial Results

Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ) today reported unaudited financial results for the second quarter and six mo...

Telik Announces Second Quarter 2009 Financial Results

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today reported a net loss of $5.7 million, or $0.11 per share, for the second quarter ended June 30, 2009, compared with a net loss of $13.6 million, or $0.26 per share, for the comparable period in 2008. ...

deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results

REYKJAVIK, Iceland, August 6 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq: DCGN ) today announced that it will report its second quarter 2009 financial results in a press release to be issued on Monday, August 10, after the close of the market in New York. The company will host a ...

Oncothyreon announces webcast of second quarter 2009 financial results conference call

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial r...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009. "We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quar...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. Total revenue for the quarter was $5,061,000 compared to total revenue of $13,660,000 for the first quarter of fiscal ye...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, includin...

PDI Reports 2009 Second Quarter Financial Results

SADDLE RIVER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII ), a leading provider of sales and marketing support to U.S. pharmaceutical companies, today reported financial and operational results for the second quarter ended June 30, 2009. Recent highligh...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

CRANBURY, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced financial results for the second quarter 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial resul...

Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast

CHICAGO, Aug. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and webcast discussing the Company's 2009 second quarter results on Tuesday, August 11, 2009 at 10:00 a.m. (EDT). Michael T. Fla...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in lin...

AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009

QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its second quarter 2009 financial and operating results before market open on Tuesday, August 11, 2009. The Co...

NxStage Reports Second Quarter 2009 Financial Results

LAWRENCE, Mass., Aug. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced net revenue for the second quarter of 2009 of $36.4 million, an increase of 15 percent when compared with revenue of $31.6 mi...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the second quarter ended June 30, 2009, and provided a corporate update. "Duri...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

REDWOOD CITY, Calif., Aug 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial results and business progress for the quarter ended June 30, 2009. Total revenue increased to $36.6 million in the second quarter of 2009 compared w...

BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009

LYNBROOK, N.Y., Aug. 4 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, announced today that the Company will host a conference call and live audio webcast at 4:30 p.m. ET on Wed...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT

NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) will hold a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT to discuss the second quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executi...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

SAN DIEGO, CA, August 4, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries,...

Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11

VENLO, The Netherlands, Aug. 4 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN ) today announced the Webcast of its second quarter 2009 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 11, and will include remarks by Peer M. Schatz, President ...

Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that it will release financial results for the second quarter of fiscal year 2009 ended June 30, 2009 on Monday, August 10, 2009. The Company will conduct a conference call and web cast t...

OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI ) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon...

Hoya Announces First Quarter Financial Results for FY2010

TOKYO, Japan, August 3 /PRNewswire-FirstCall/ -- HOYA Corporation today announced financial results for the first quarter ended June 30, 2009. Net sales were 94.9 billion yen for the quarter, a 27.0% decrease from 130.1 billion yen in the same period last year, and operating income was 9.2 bil...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief execut...

Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call

ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) today announced that it will report its 2009 second quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, August 7, 2009. The Company will hold an investor conference ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

SAN MATEO, Calif., July 31 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, August 7, 2009 at 9:00 a.m. ET (6:00 a.m. PT...

CuraGen Reports Second Quarter 2009 Financial Results

BRANFORD, Conn., July 31 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) today reported its financial results for the second quarter of 2009 and announced that it had further reduced its outstanding convertible debt and reached an agreement in principle, expr...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and program highligh...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter. Tota...
Other Tags
(Date:7/24/2014)... of biodiversity and one of the most species richness ... world. However, current levels of diversity might be still ... increase in the description of new endemic species of ... and availability of samples for DNA analysis. , ... and morphological analysis, researchers from the University of ...
(Date:7/24/2014)... is currently conducting research into the potato genes that ... by a reduction in rainfall and increased extremes of ... most resistant genes in order to create new potato ... research is also seeking to find out how the ... greater drought and higher and lower temperatures. , This ...
(Date:7/24/2014)... German . ... sufferers worldwide, a further 600 million people living with ... population contending with allergic rhinitis (allergic inflammation of the ... organs and parts of the body beyond the respiratory ... form of inflammatory bowel diseases such as colitis ulcerosa), ...
Breaking Biology News(10 mins):A tiny new species of frog from Brazil with a heroic name 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... device or surgical implant is put inside the human ... Guillermo Ameer, most of the time, that response can ... will always get an inflammatory response to some degree," ... School of Engineering and Applied Science and professor of ... with commonly used plastic materials, in particular, is that ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... is possible to predict long-term cancer risk from a chemical ... The findings, which currently appear in the journal PLOS ... cheaper tests to screen chemicals for their potential cancer causing ... of and mortality from cancer, about 40 percent of Americans ... around 20 percent will die of it. Currently fewer than ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
Breaking Medicine News(10 mins):Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Antioxidant biomaterial promotes healing 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
Other Contents